Key Highlights

  • The Carlisle-based company, known as Carr's Group until October 2025, announced on 11 August 2026 that it had sold Chirton Engineering, the last remnant of its Engineering division, for up to £0.85m.
  • What remains is a pure-play livestock supplements Business with factories in the UK, the US and, since December 2025, Brazil.
  • Shares last traded at 137p, valuing the group at roughly £71m.
  • Chirton was the only business left from the Engineering division, the bulk of which went to Cadre Holdings in April 2025 at a £75m enterprise value.
  • The disposal caps a sequence that included a £70m tender offer in June 2025, which repurchased 42.9m shares (45% of the issued capital) at 163p, and the change of name.

Fevara PLC (LSE:FVA) has just closed the book on a two-year transformation. The Carlisle-based company, known as Carr's Group until October 2025, announced on 11 August 2026 that it had sold Chirton Engineering, the last remnant of its Engineering division, for up to £0.85m. What remains is a pure-play livestock supplements business with factories in the UK, the US and, since December 2025, Brazil.

The question now is what comes next. With the financial year having ended on 31 August 2026 and a trading update likely within weeks, the market will soon learn whether a strong first half and two Brazilian acquisitions add up to the growth story management has set out. Shares last traded at 137p, valuing the group at roughly £71m.

Chirton sale completes the strategic refocus

The 11 August 2026 announcement confirmed the sale of Chirton Engineering Ltd to Deca Group, a UK engineering company, for £0.65m in cash on completion plus £0.2m deferred over two years, on a cash-free, debt-free basis. Chirton was the only business left from the Engineering division, the bulk of which went to Cadre Holdings in April 2025 at a £75m enterprise value.

The sum is small but the significance is symbolic. Chief executive Joshua Hoopes said the group was "delighted to have achieved the final milestone in our strategic journey to simplify our operations and focus the business as a pure play international specialist in livestock supplements," adding that Fevara is "well positioned to continue to drive long-term value for all stakeholders."

The disposal caps a sequence that included a £70m tender offer in June 2025, which repurchased 42.9m shares (45% of the issued capital) at 163p, and the change of name. The April interim statement had flagged a Chirton sale for the second half of calendar 2026.

What Fevara does

Fevara (LSE:FVA) develops, manufactures and markets nutritional supplements for cattle and sheep, chiefly feed licks, low-moisture blocks, bagged minerals and boluses, under brands including Crystalyx, Horslyx and Scotmin Nutrition. Products are sold in more than 20 countries from sites in the UK, the US and Brazil.

In FY25 (year to 31 August 2025) UK/Europe generated Revenue of £41.4m and US Agriculture £37.4m, with joint ventures adding £1.35m of post-tax profit. Brazil is the new growth leg: Macal, a supplements distributor in Campo Grande bought in December 2025 for £5.0m initial consideration, was followed in March 2026 by a £4.3m purchase of a production Facility and mineral distribution business in São Paulo state, giving access to territory holding around 100 million head of cattle. Local block production is expected from the second quarter of 2027.

Demand is seasonal: the northern hemisphere winter falls in Fevara's first half (September to February), so H1 profit typically exceeds the full-year figure.

H1 FY26: flat revenue, sharply higher profit

Interim results for the six months to 28 February 2026, published on 22 April, showed revenue of £50.6m, flat year on year and up 2% at constant currency. Adjusted operating profit rose 22% to £7.2m (H1 FY25: £5.9m), lifting the adjusted EBIT Margin to 14.2% from 11.7%. Adjusted profit before tax was £7.0m (H1 FY25: £5.9m) and adjusted EPS more than doubled to 11.0p on the smaller post-tender share count. Reported operating profit was £5.9m (H1 FY25: £7.7m) and basic EPS 8.9p (H1 FY25: 7.5p).

UK/Europe drove the improvement, with adjusted operating profit up 26% to £3.7m on 9% growth in block volumes and a planned 14% cut in lower-margin minerals. The US contributed £2.7m, up 5%, as 28% Volume growth in the southern states offset an 11% decline in the north after an unusually warm winter.

Net unrestricted cash fell to £1.4m at 28 February 2026 from £15.7m a year earlier, after a £4.1m net outflow from the Engineering sale and tender offer, £4.5m placed in a pension escrow, the £5.0m Macal payment and £3.8m of dividends. A £20m committed HSBC facility was arranged in November 2025. The interim Dividend was held at 1.2p.

For context, FY25 continuing revenue was £78.8m, up 4.1%, with adjusted operating profit of £3.7m (FY24: £2.2m) and a total dividend of 2.4p. In April the board said it was confident of a full-year outcome in line with market expectations, citing company-compiled consensus of £5.5m adjusted operating profit for FY26.

What could drive the stock next?

The nearest catalyst is the FY26 trading update. Last year it arrived on 23 September, with full-year results on 10 December, so a similar timetable would bring news within weeks, along with early commentary on the FY27 winter season.

Brazil is the longer-term lever. The acquired businesses were around breakeven at the interim stage; the market will want evidence of the Earnings accretion promised for Macal and progress towards local production in 2027. Fevara's medium-term ambitions are revenue of at least £120m, EBITDA of at least £15m, an EBIT margin of at least 10% and return on capital employed of at least 20% within three to five years.

Partnerships add optionality, including a five-year exclusive agreement signed in April 2026 to distribute Oceana Minerals' LithoNutri in Great Britain and Ireland. Management also intends to move to a progressive dividend with minimum two-times cover.

Risks investors should watch

Weather is the most immediate risk: a mild winter in the northern US cost 11% of volume there in H1 FY26, and a repeat would weigh on the group's most profitable period. Because the second half typically loses money, the full-year figure is highly sensitive to any slippage in H2 trading.

The Balance Sheet has changed markedly. Unrestricted net cash of £1.4m compares with £15.7m a year earlier, the group now leans on bank facilities, and a further £4.3m went on the São Paulo purchase after the period end, with deferred payments due in 2027 and 2028. Brazil also brings execution and currency risk in a market where Fevara has no operating history.

Governance drew attention when 39.26% of votes were cast against the re-election of non-executive director Gillian Watson at the February 2026 AGM, which the board attributed to two missed meetings. Farm incomes, livestock prices and input costs are outside the company's control, and with a Market Value near £71m the shares may offer limited liquidity.

Outlook

Fevara enters FY27 as a simpler, smaller and more profitable business than the Carr's Group of two years ago, with explicit medium-term targets and a first half that beat the prior year on every adjusted measure. The coming months will show whether the second half kept the full year on track with the £5.5m consensus, how quickly Brazil moves towards accretion, and whether the progressive dividend intent is confirmed in December. The 52-week range of 114.5p to 149.5p suggests the market is still weighing the growth case against the cash consumed in building it.